Biomarin Pharmaceutical Inc (BMRN)

Pretax margin

		Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	237,353	188,563	151,678	108,105	72,146	149,576	100,560	56,304	35,609	-75,350	-55,636	-70,692	-127,121	-48,997	-11,918	59,120	59,498	-94,811	-128,341	-157,576
Revenue (ttm)	US$ in thousands	2,443,023	2,373,030	2,261,604	2,184,719	2,123,138	2,059,481	1,999,471	1,903,678	1,871,615	1,827,451	1,829,463	1,891,778	1,815,339	1,822,817	1,822,364	1,813,337	1,772,797	1,694,305	1,597,556	1,518,971
Pretax margin		9.72%	7.95%	6.71%	4.95%	3.40%	7.26%	5.03%	2.96%	1.90%	-4.12%	-3.04%	-3.74%	-7.00%	-2.69%	-0.65%	3.26%	3.36%	-5.60%	-8.03%	-10.37%

March 31, 2024 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $237,353K ÷ $2,443,023K
= 9.72%

Biomarin Pharmaceutical Inc's pretax margin has shown variability over the past few quarters. The company's pretax margin has improved from -10.37% in Jun 2019 to 9.72% in Mar 2024, indicating a positive trend in profitability. However, it is important to note that the pretax margin fluctuated during this period, with some quarters showing lower margins such as -4.12% in Dec 2021 and 1.90% in Mar 2022.

Overall, Biomarin Pharmaceutical Inc has demonstrated an upward trend in pretax margin, reflecting improved operational efficiency and cost management strategies. The company's ability to consistently increase its pretax margin indicates a positive financial performance and may suggest a strengthening position in the pharmaceutical industry.